Anaïs
Corma Gómez
Publicaciones en las que colabora con Anaïs Corma Gómez (10)
2023
-
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596
2022
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2021
-
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response
AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127
-
Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 5, pp. e96-e102
-
Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 9, pp. 2375-2379
2020
-
Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362
2019
-
A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)
Liver International, Vol. 39, Núm. 10, pp. 1918-1926
-
Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection
Scientific Reports, Vol. 9, Núm. 1
-
HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals
AIDS, Vol. 33, Núm. 7, pp. 1167-1174
-
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks
Journal of Infection, Vol. 79, Núm. 1, pp. 30-35